
Keywords: متابولیسم فاز I; Bosentan; Perfluorinated analogues; Metabolic specificity; Phase I metabolism; HLM; Cl; Clearance; CYP; Cytochrome P450; DDI; drug-drug interactions; ERA; Endothelin Receptor Antagonist; ET-1; Endothelin 1; ETA; Endothelin receptor A; ETB; Endothelin rece